FXN - Foreign Currency Neutral | |
(1) | Includes adjustments related to the purchase accounting for acquisitions impacting identified intangible assets and valuation of fixed assets and debt. The amount in 2018 also included a fair value step-up adjustment of $478 million recorded relative to Bard's inventory on the acquisition date. |
(2) | Represents restructuring and integration costs associated with the Bard and CareFusion acquisitions, as well as restructuring costs associated with other portfolio rationalization initiatives. |
(3) | Represents transaction costs primarily associated with the Bard acquisition. |
(4) | Represents financing impacts associated with the Bard acquisition. |
(5) | Represents losses recognized upon the extinguishment of certain long-term senior notes. |
(6) | Represents the net amount recognized in the period related to BD's sale of its non-controlling interest in Vyaire Medical, partially offset by $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit as well as $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit. |
(7) | Represents the dilutive impact of BD shares issued in May 2017, in anticipation of the Bard acquisition and BD shares issued as consideration transferred to acquire Bard. The adjusted diluted average shares outstanding (in thousands) was 260,758. |
(8) | Includes additional tax expense, net, of $640 million relating to new U.S. tax legislation. |
